Corporate report

Drug strategy 2016: development review

A review of the evidence on the 2016 drug strategy by the Advisory Council on the Misuse of Drugs (ACMD).


ACMD response to drug strategy 2016

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This ACMD report provides a summary of key points and recommendations on the 2016 skeleton drug strategy.

Published 14 July 2017